C4 Therapeutics (CCCC) Net Margin (2019 - 2025)
Historic Net Margin for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to 286.43%.
- C4 Therapeutics' Net Margin fell 1258600.0% to 286.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 395.51%, marking a year-over-year decrease of 821700.0%. This contributed to the annual value of 295.96% for FY2024, which is 3423700.0% up from last year.
- Latest data reveals that C4 Therapeutics reported Net Margin of 286.43% as of Q3 2025, which was down 1258600.0% from 402.6% recorded in Q2 2025.
- In the past 5 years, C4 Therapeutics' Net Margin registered a high of 77.99% during Q4 2021, and its lowest value of 1348.42% during Q2 2023.
- In the last 5 years, C4 Therapeutics' Net Margin had a median value of 363.66% in 2025 and averaged 516.35%.
- As far as peak fluctuations go, C4 Therapeutics' Net Margin tumbled by -12249200bps in 2022, and later skyrocketed by 12008600bps in 2024.
- Quarter analysis of 5 years shows C4 Therapeutics' Net Margin stood at 77.99% in 2021, then tumbled by -1571bps to 1302.91% in 2022, then grew by 18bps to 1065.75% in 2023, then skyrocketed by 37bps to 667.82% in 2024, then soared by 57bps to 286.43% in 2025.
- Its last three reported values are 286.43% in Q3 2025, 402.6% for Q2 2025, and 363.66% during Q1 2025.